John C. Bell
Fundador en Turnstone Biologics, Inc. .
Perfil
John C.
Bell was the founder of SillaJen Biotherapeutics, Inc. founded in 2006, where he held the title of Director & Chief Scientific Officer from 2009 to 2010.
Dr. Bell is also the founder of Turnstone Biologics, Inc. Dr. Bell's current jobs include being a Professor-Medicine at the University of Ottawa and a Senior Scientist at the Ottawa Health Research Institute.
Dr. Bell's former jobs include being a Director at The Canadian Cancer Society and a Member-Clinical Trials Group at the National Cancer Institute of Canada.
Dr. Bell received a doctorate degree from McMaster University.
Cargos activos de John C. Bell
| Empresas | Cargo | Inicio |
|---|---|---|
| University of Ottawa | Corporate Officer/Principal | - |
| Ottawa Health Research Institute | Corporate Officer/Principal | - |
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Fundador | - |
Antiguos cargos conocidos de John C. Bell.
| Empresas | Cargo | Fin |
|---|---|---|
| National Cancer Institute of Canada | Corporate Officer/Principal | - |
The Canadian Cancer Society
 The Canadian Cancer Society Miscellaneous Commercial ServicesCommercial Services The Canadian Cancer Society operates as a non-profit organization that provides cancer charity services. It offers support and services and programs for the prevention and screening of cancer. The company was founded in 1938 and is headquartered in Toronto, Canada. | Director/Miembro de la Junta | - |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Fundador | - |
Formación de John C. Bell.
| McMaster University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
| Ottawa Health Research Institute | |
The Canadian Cancer Society
The Canadian Cancer Society Miscellaneous Commercial ServicesCommercial Services The Canadian Cancer Society operates as a non-profit organization that provides cancer charity services. It offers support and services and programs for the prevention and screening of cancer. The company was founded in 1938 and is headquartered in Toronto, Canada. | Commercial Services |
| National Cancer Institute of Canada | |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- John C. Bell
